

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study

Mathilde Hunault-Berger,¹ Thibaut Leguay,² Xavier Thomas,³ Ollivier Legrand,⁴ Françoise Huguet,⁵ Caroline Bonmati,⁶ Martine Escoffre-Barbe,⁷ Laurence Legros,⁸ Pascal Turlure,⁹ Patrice Chevallier,¹⁰ Fabrice Larosa,¹¹ Frederic Garban,¹² Oumedaly Reman,¹³ Philippe Rousselot,¹⁴ Nathalie Dhédin,¹⁵ André Delannoy,¹⁶ Marina Lafage-Pochitaloff,¹⁷ Marie Christine Béné,¹⁸ Norbert Ifrah,¹⁷ and Hervé Dombret¹⁹ for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)

Hematology Departments of Angers,¹ Bordeaux,² Lyon,³ Hotel Dieu AP-HP Paris,⁴ Toulouse,⁵ Nancy,⁶ Rennes,⁷ Nice,⁸ Limoges,⁹ Nantes,¹⁰ Besancon,¹¹ Grenoble,¹² Caen,¹³ Versailles,¹⁴ Pitié-Salpêtrière AP-HP Paris,¹⁵ Jolimont Belgique,¹⁶ Genetic Department¹⁷ of AP-HM Marseille; Immunology Department of Nancy,¹⁸ and Hematology Department of Saint-Louis AP-HP Paris, France¹⁹

Citation: Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhédin N, Delannoy A, Lafage-Pochitaloff M, Béné MC, Ifrah N, and Dombret H for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. *Haematologica* 2011;96(2):245-252. doi:10.3324/haematol.2010.027862

Online Supplementary Figure S1.

Consort Flowchart GRAALL-SA1 Study

